著者

景山 孝正 大野 文俊 安田 行寛 新藤 恭司 三谷 鳴夫 丸伝 章 赤沢 明

出版者

一般社団法人 日本臨床薬理学会

雑誌

臨床薬理 (ISSN:03881601)

巻号頁・発行日

vol.10, no.4, pp.525-533, 1979

被引用文献数

1

---

The biological fate of suxibuzone (SB), a new non-steroidal anti-inflammatory agent, was studied in healthy male volunteers with single oral doses and compared with that of phenylbutazone (PB) by a cross-over test, with the following results:<BR>1) PB, oxyphenbutazone (Oxy-PB), and &gamma;-hydroxy-phenylbutazone (&gamma;-Hydroxy-PB) were identified in plasma after oral administration of SB. Moreover these metabolites, their glucuronides, SB-glucuronide, 4-hydroxymethyl-phenylbutazone (4-HM-PB)-glucuronide, and <I>p</I>, &gamma;-dihydroxy-phenylbutazone (<I>p</I>, &gamma;-DH-PB) were found in urine.<BR>2) Peak plasma concentration of the metabolites was obtained 4 hrs after a single oral dose of 426 mg of SB when the concentration of PB, the main metaboliteof SB, was 36&mu;g/ml, much the same as the corresponding level in the volunteers receiving PB. On the other hand, there was no difference between volunteers receiving SB and PB interms of the concentration of Oxy-PB. But the concentration of &gamma;-Hydroxy-PB was higher after oral SB than after oral PB.<BR>3) Urinary excretion of the metabolites was about 8% of the administered dose up to 16 8hrs after oral doses of SB or PB, but in the period shortly after oral doses of SB, Oxy-PB-glucuronide and &gamma;-Hydroxy-PB were excreted to ag reater extent than after oral doses of PB.<BR>4) From these results in the plasma and urine after oral doses of SB, it was found that SB may be characterized as a prodrug of PB.<BR>5) During the experiment, no side effects or abnormalities were observed in the medical examination and laboratory test except for a slight decrease in the uric acid level in plasma.